KRAS and non-small cell lung carcinoma: This present study indicated that a panel of molecular markers could be applied, in conjunction with our constructed membrane-array method with weighted calculation, to detect activating KRAS status from circulating RNA in the peripheral blood of NSCLC and CRC patients.